
基因编辑细胞系
背景说明
人类遗传染色体组添加也是种对靶人类遗传染色体组或转录代谢物能够 敲除、加入和指定点甲基化等明确突显的人类遗传染色体组工程建筑科技,包括能够 工人核酸酶实现要求对人类遗传染色体组组的不同人类遗传染色体组编码序列的敲除、加入或明确突显。CRISPR平台可批量化地敲除或过表示个别人类遗传染色体组,于是也可以作需求要求人类遗传染色体组,配个合相对的技能工作,能够寻得该我的生命项目或肠道疾病中的要素要求人类遗传染色体组。服务流程
1. 意项定量分析- 人类基因队列评估报告格式与数据分析
- 时间间隔、安全隐患点评价指标
- 质粒打造
- 病毒是什么包装箱
- 细菌感化
- PB转座子装置
- RNP
- 单克隆化
- 单克隆淘汰
- PCR/qRCR/WB/流式细胞等
- 支原体灭菌加测、种植线性等
服务内容
工程专业的制定和加测销售团队,可提高各种载体建立、过把你想表达出来、要素、DNA敲除、DNA敲入稳转神经元株建立及宏hiv病毒包装设计与妇科影响贴心服务。建立控制系统多样化,涉及但不的局是指CRISPR、Tet-On、PB转座子、慢宏hiv病毒妇科影响及质粒瞬转控制系统。服务类型 | 周期 | 交付标准 | 相关检测 |
基因敲除(KO) | 稳转Cell Pool(4周起) | 稳转Cell Pool,1*2管 | 方式、PCR+测序 |
基因点突变(PM) | 稳转Cell Pool(6周起) | 政策、PCR+测序 | |
基因敲入(KI) | 稳转Cell Pool(6周起) | 攻略 、PCR+测序 | |
靶点过表达出稳转 | 稳转Cell Pool(6周起) | 战略、PCR+淀粉酶检 | |
Luc过传达稳转株 | 稳转Cell Pool (3周起) | 普鲁士蓝染色+体内Luc论文检测 |
服务优势
- 的技术完善
- 游戏精明能干多样
- 服务的完整
- 质控认真
Cancer Types | List of WT Cell Lines | List of Modified Cell Lines | Background |
Breast Cancer | 4T1 | hPDL1(Tg)-mPdl1(KO) | BALB/c |
hPDL1(Tg)-mPdl1(KO)-hCD47(Tg)-mCd47(KO) | |||
hHER2 (Tg) | |||
hHER2(Tg)-hCD47(Tg)-mCd47(KO) | |||
hEGFRVIII (Tg)-mEGFRVIII(KO) | |||
hEGFR (Tg)-mEgfr(KO) | |||
hEpCAM(Tg)-mEpcam(KO) | |||
hNECTIN4 (Tg)-mNectin4(KO) | |||
hGCPII (Tg)-mGcpII(KO) | |||
EMT6 | hPDL1(Tg)-mPdl1(KO) | BALB/c | |
hPDL1(Tg)-mPdl1(KO)-hCD47(Tg)-mCd47(KO) | |||
hCD39(Tg)-mCd39(KO) | |||
Colorectal Cancer | CT26 | hPDL1(Tg)-mPdl1(KO) | BALB/c |
hPDL1(Tg)-mPdl1(KO)-hCD24(Tg)-mCd24(KO) | |||
hPDL1(Tg)-mPdl1(KO)-hCD39(Tg)-mCd39(KO) | |||
hPDL1(Tg)-mPdl1(KO)-hCD47(Tg)-mCd47(KO) | |||
hPDL1(Tg)-mPdl1(KO)-hCD73(Tg)-mCd73(KO) | |||
hPDL1(Tg)-mPdl1(KO)-hCD39(Tg)-mCd39(KO)-hCD73(Tg)-mCd73(KO) | |||
hPDL1(Tg)-mPdl1(KO)-hNECTIN2(hCD112)(Tg) -mNectin2(mCd112)(KO) | |||
hPDL1(Tg)-mPdl1(KO)-hCD155(Tg)-mCd155(KO) | |||
hPDL1(Tg)-mPdl1(KO)-hB7H3(Tg)-mB7h3(KO) | |||
hPDL1(Tg)-mPdl1(KO)-hTNFR2 (Tg)-mTnfr2(KO) | |||
hPDL1(Tg)-mPdl1(KO)-mCLDN18.2(Tg) | |||
hPDL1(Tg)-mPdl1(KO)-hVEGFA(Tg)-mVegfa(KO) | |||
hPDL1(Tg)-mPdl1(KO)-hHVEM(Tg)-mHvem(KO) | |||
hCD30(Tg)-mCd30(KO) | |||
hCD47 (Tg)-mCd47(KO) | |||
hCD47(Tg)-mCd47(KO)-mPdl1(KO) | |||
hCD47(Tg)-mCd47(KO)-hCD24(Tg)-mCd24(KO) | |||
hCD70(Tg)-mCd70(KO) | |||
hCD73 (Tg)-mCd73(KO) | |||
hCD155(Tg)-mCd155(KO) | |||
hHER2 (Tg) | |||
hHER2(Tg)-mHer2(KO) | |||
hHER2(Tg)-hHER3(Tg) | |||
hHER2(Tg)-hHER3(Tg)-mHer3(KO) | |||
hEGFR (Tg)-mEgfr(KO) | |||
hCD24(Tg)-mCd24(KO) | |||
hNECTIN4 (Tg)-mNectin4(KO) | |||
h5T4(Tg)-m5t4(KO) | |||
mB2m(KO) | |||
mB2M(KO)-hB2M-hHLA-G(Tg) | |||
HLA-E-hB2M-Peptide(Tg) | |||
hClaudin18.2(Tg)-mClaudin18.2(KO) | |||
hCEACAM5(Tg)-mCeacam5(KO) | |||
hDLL3(Tg)-mDll3(KO) | |||
hGDF15(Tg)-mGdf15(KO) | |||
hGPRC5D(Tg)-mGprc5d(KO) | |||
hLRRC15(Tg)-mLrrc15(KO) | |||
hROR1(Tg)-mRor1(KO) | |||
hSSTR2(Tg)-mSstr2(KO) | |||
hTNFR2 (Tg)-mTnfr2(KO) | |||
hTACSTD2(Tg) | |||
hTACSTD2(Tg)-mTacstd2(KO) | |||
hVEGFA(Tg)-mVegfa(KO) | |||
hVTCN1(Tg)-mVtcn1(KO) | |||
MC38 | hPDL1(Tg)-mPdl1(KO) | C57BL/6 | |
hPDL1(Tg)-mPdl1(KO)-hCD24A(CD24)(Tg)-mCd24A(Cd24)(KO) | |||
hPDL1(Tg)-mPdl1(KO)-hCD47(Tg)-mCd47(KO) | |||
hPDL1(Tg)-mPdl1(KO)-hCD73(Tg)-mCd73(KO) | |||
hPDL1(Tg)-mPdl1(KO)-hB7H3(Tg)-mB7h3(KO) | |||
hPDL1(Tg)-mPdl1(KO)-mClaudin18.2(Tg) | |||
hCD24A(CD24)(Tg)-mCd24A(Cd24)(KO) | |||
hCD30(Tg)-mCd30(KO) | |||
hCD38(Tg)-mCd38(KO) | |||
hCD47 (Tg)-mCd47(KO) | |||
hCD47(Tg)-mCd47(KO)-hCd24(Tg)-mCd24(KO) | |||
hCD70(Tg)-mCd70(KO) | |||
hCD73 (Tg) | |||
hHER2(Tg) | |||
hHER2(Tg)-mHer2(KO) | |||
hEGFR(Tg)-mEgfr(KO) | |||
hNECTIN4 (Tg)-mNectin4(KO) | |||
mBcma(Tg) | |||
hClaudin18.2(Tg)-mClaudin18.2(KO) | |||
hCEACAM5(Tg)-mCeacam5(KO) | |||
hCSF1(Tg)-mCsf1(KO) | |||
hFAP(Tg)-mFap(KO) | |||
mGdf15(TG) | |||
hGDF15(Tg)-mGdf15(KO) | |||
hHLA2(Tg) | |||
hROR1(Tg)-mRor1(KO) | |||
hSIGLEC15 (Tg)-mSiglec15(KO) | |||
mStk11(KO) | |||
hTACSTD2(Tg) | |||
hTACSTD2(Tg)-mTacstd2(KO) | |||
hTNFR2 (Tg)-mTnfr2(KO) | |||
Lymphoma | A20 | hCD19(Tg)-mCd19(KO)-Luc | BALB/c |
hCD20(Tg) | |||
hCD20(Tg)-mCd20(KO)-Luc | |||
hPDL1(Tg)-mPdl1(KO)-Luc | |||
hGPRC5D (Tg)-mGprc5d(KO) | |||
MOPC315 | hBCMA(Tg)-mBcma(KO) | BALB/c | |
J558 | mBcma(Tg) | BALB/c | |
Melanoma | B16F10 | hPDL1(Tg)-mPdl1(KO) | C57BL/6 |
A375 | hHLA-G(Tg) | Human | |
Lung Cancer | LLC1 | hSIGLEC15(Tg)-mSiglec15(KO) | C57BL/6 |
Liver Cancer | H22 | hPDL1(Tg)-mPdl1(KO) | BALB/c |
hPDL1(Tg)-mPdl1(KO)-Luc | |||
hPDL1(Tg)-mPdl1(KO)-hCD47(Tg)-mCd47(KO) | |||
hPDL1(Tg)-mPdl1(KO)-hNECTIN2(hCD112)(Tg) mNectin2(mCd112)(KO) | |||
Gastric Carcinoma | NUGC4 | hClaudin18.2(Tg)-mClaudin18.2(KO)-Luc | Human |